Effects of the phosphodiesterase 4 inhibitors SB 207499 and AWD 12-281 on the inflammatory reaction in a model of allergic dermatitis

被引:19
作者
Bäumer, W
Gorr, G
Hoppmann, J
Ehinger, AM
Ehinger, B
Kietzmann, M
机构
[1] Sch Vet Med, Dept Pharmacol Toxicol & Pharm, D-30559 Hannover, Germany
[2] Sch Vet Med, Dept Pathol, D-30559 Hannover, Germany
关键词
allergy; dermatitis; phosphodiesterase; 4; inhibitor; AWD; 12-281; SB; 207499; toluenediisocyanate;
D O I
10.1016/S0014-2999(02)01810-1
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The inhibitors of the phosphodiesterase 4, SB 207499 (cilomilast, c-4-cyano-4-(3-cyclopentyloxy-4-methoxy-phenyl)-r-L-cyclohexane carboxylic acid) and AWD 12-281 (N-(3,5-dichloropyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl]-glyoxylic acid amide) were tested in a model of allergic dermatitis in mice. To obtain an allergic dermatitis, BALB/c mice were sensitized to toluene-2,4-diisocyanate. The allergic reaction was challenged by topical administration of toluene-2,4-diisocyanate onto the mice ears. Before challenge, two groups of mice were treated topically (ear skin) with SB 207499 or AWD 12-281. There was a significant ear swelling in toluene-2,4-diisocyanate-challenged mice ears 4, 8, 16, 24 and 48 h after challenge. SB 207499 and AWD 12-281 inhibited this swelling significantly 8, 16, 24 and 48 h after the challenge. For biochemical parameters and histology, ears were sampled from mice sacrificed 4, 8 and 16 h after the challenge. In homogenized tissue, SB 207499 and AWD 12-281 inhibited significantly the secretion of interleukin 1beta induced by toluene-2,4-diisocyanate 4 and 8 h after challenge. T:he cell influx (granulocytes) observed in the toluene-2,4-diisocyanate-challenged mice 8 and 16 h after challenge was nearly abolished by AWD 12-281 and SB 204799. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:195 / 200
页数:6
相关论文
共 30 条
[1]   INCREASED LEUKOCYTE HISTAMINE-RELEASE WITH ELEVATED CYCLIC AMP-PHOSPHODIESTERASE ACTIVITY IN ATOPIC-DERMATITIS [J].
BUTLER, JM ;
CHAN, SC ;
STEVENS, S ;
HANIFIN, JM .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1983, 71 (05) :490-497
[2]   Cyclic nucleotide phosphodiesterase 4 subtypes are differentially expressed by primary keratinocytes and human epidermoid cell lines [J].
Chujor, CSN ;
Hammerschmid, F ;
Lam, C .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1998, 110 (03) :287-291
[3]   PHOSPHODIESTERASE INHIBITION BY RO 20-1724 REDUCES HYPER-IGE SYNTHESIS BY ATOPIC-DERMATITIS CELLS-INVITRO [J].
COOPER, KD ;
KANG, K ;
CHAN, SC ;
HANIFIN, JM .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1985, 84 (06) :477-482
[4]   Murine mast cells exposed to mercuric chloride release granule-associated N-acetyl-β-D-hexosaminidase and secrete IL-4 and TNF-α [J].
Dastych, J ;
Walczak-Drzewiecka, A ;
Wyczolkowska, J ;
Metcalfe, DD .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1999, 103 (06) :1108-1114
[5]  
DENT G, 1994, J PHARMACOL EXP THER, V271, P1167
[6]   Effects of the phosphodiesterase 4 inhibitor RPR 73401 in a model of immunological inflammation [J].
Ehinger, AM ;
Gorr, G ;
Hoppmann, J ;
Telser, E ;
Ehinger, B ;
Kietzmann, M .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2000, 392 (1-2) :93-99
[7]   EARLY MOLECULAR EVENTS IN THE INDUCTION-PHASE OF CONTACT SENSITIVITY [J].
ENK, AH ;
KATZ, SI .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (04) :1398-1402
[8]   Requirement of additional adenylate cyclase activation for the inhibition of human eosinophil degranulation by phosphodiesterase IV inhibitors [J].
Ezeamuzie, CI .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2001, 417 (1-2) :11-18
[9]   DEVELOPMENT AND VALIDATION OF AN ALTERNATIVE DERMAL SENSITIZATION TEST - THE MOUSE EAR SWELLING TEST (MEST) [J].
GAD, SC ;
DUNN, BJ ;
DOBBS, DW ;
REILLY, C ;
WALSH, RD .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 1986, 84 (01) :93-114
[10]   In vitro differentiation of human monocytes to macrophages: Change of PDE profile and its relationship to suppression of tumour necrosis factor-alpha release by PDE inhibitors [J].
Gantner, F ;
Kupferschmidt, R ;
Schudt, C ;
Wendel, A ;
Hatzelmann, A .
BRITISH JOURNAL OF PHARMACOLOGY, 1997, 121 (02) :221-231